Thrivent Financial For Lutherans Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Thrivent Financial For Lutherans

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$83.14 - $145.99 $43.6 Million - $76.6 Million	-525,010 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$110.08 - $142.92 $17.2 Million - $22.4 Million	-156,662 Reduced 22.98%	525,010 $62.3 Million
Q4 2021 Feb 16, 2022	BUY	$99.73 - $148.48 $68 Million - $101 Million	681,672 New	681,672 $93.9 Million
Q3 2021 Nov 15, 2021	SELL	$98.85 - $138.91 $140 Million - $197 Million	-1,416,890 Closed	0 $0
Q2 2021 Aug 19, 2021	BUY	$65.78 - $105.02 $60.5 Million - $96.6 Million	919,951 Added 185.12%	1,416,890 $138 Million
Q1 2021 May 17, 2021	BUY	$64.07 - $91.75 $111,417 - $159,553	1,739 Added 0.35%	496,939 $34 Million
Q4 2020 Feb 16, 2021	SELL	$65.07 - $98.24 $161,894 - $244,421	-2,488 Reduced 0.5%	495,200 $42.4 Million
Q3 2020 Nov 10, 2020	BUY	$59.04 - $77.95 $19.6 Million - $25.9 Million	332,014 Added 200.4%	497,688 $32.4 Million
Q2 2020 Aug 12, 2020	BUY	$29.01 - $74.23 $1.88 Million - $4.81 Million	64,811 Added 64.26%	165,674 $12.1 Million
Q1 2020 May 15, 2020	BUY	$27.51 - $57.29 $2.77 Million - $5.78 Million	100,863 New	100,863 $3.43 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.